Pediatric oncology patients frequently require parenteral nutrition (PN) because of difficulties in swallowing or other impediments to enteral nutrition. The administration of PN increases the risk of catheter-related complications, such as bloodstream infection and catheter occlusion. This study examined the effect of catheter type on the frequency of these complications during PN administration, comparing patients with totally implantable subcutaneous port (hereafter, ports) with those with external catheters.
Introduction
Long-term CVCs are an essential component of medical care for pediatric oncology patients. They provide reliable venous 624087P ENXXX10.1177/0148607115624087Journal of Parenteral and Enteral NutritionShenep et al research-article2015 access for medication and fluid administration, collection of blood for laboratory testing, and nutrition support with PN when required. However, complications related to CVCs cause significant morbidity among pediatric patients with cancer; these complications include central line-associated bloodstream infection (CLABSI), occlusion of the CVC, and intravascular thrombosis.
1,2 PN is commonly required in pediatric patients undergoing treatment for cancer who develop gastrointestinal dysfunction or malnutrition, with 30% of the patients in one study receiving PN during the course of therapy. 3, 4 Past studies have indicated that PN administration is an important risk factor for many catheterrelated complications. 3, 5 There is limited information about the risk factors for catheter-related complications during PN treatment in pediatric oncology patients. In other patient populations, the catheter type may contribute to the risk; for example, some studies of patients receiving PN found that the risk of CLABSI was higher in those with ports than in those with external CVCs, [6] [7] [8] but others have found the opposite [9] [10] [11] or no apparent difference. [12] [13] [14] Because previous studies have shown that pediatric oncology patients with ports have a much lower rate of catheter-related complications than do those with external CVCs, the use of ports is preferred where feasible. 1, [15] [16] [17] However, the effect of CVC type on the relative risk of complications in pediatric oncology patients during PN administration has not been well explored, so there is insufficient evidence to guide CVC choice in that setting. 3 Furthermore, the clinical consequences of complications related to ports are often more serious than those related to external CVCs because port infections are more difficult to eradicate and because surgery to replace these devices is more complicated. 18, 19 This study was designed to assess the effect of CVC type and other clinical variables on CVC-related complications during PN administration in children with cancer.
Methods

Setting and Institutional Review
This retrospective matched cohort study was conducted at St. Jude Children's Research Hospital, a 68-bed pediatric oncology referral center located in the southeast United States. The study was approved by the hospital's Institutional Review Board before data collection was initiated (XPD14-043).
Selection of Participants
The study included 2 cohorts: cohort 1 consisted of patients receiving PN through a port, and cohort 2 consisted of a matched group of patients receiving PN through an external CVC. The external CVCs included peripherally inserted central catheters and external tunneled catheters (Hickman or Broviac). To identify eligible participants, the pharmaceutical database was queried for all PN orders entered between January 1, 2006, and May 2, 2014, and the results were compared against a list of documented CVC types. The type of CVC in place during PN administration was verified by manual chart review. Fifty consecutive individuals were identified for cohort 1 (PN administered through a port), and matched participants were sought by chart review to complete cohort 2 (PN administered through an external CVC), according to an algorithm developed to identify a well-matched cohort. The participants were matched on a 1:1 basis. The algorithm accounted for the patient's age at diagnosis (±5 years), the type of malignant neoplasm, whether the patient had undergone hematopoietic stem cell transplantation, and the presence of severe malignant disease (defined as relapsed malignancy, chemotherapeutic treatment failure, or death from malignant disease during the study period). Supplementary Figure S1 shows the branched matching algorithm.
Data Collection
Data were collected concerning the demographics, comorbidities, and treatment of the primary malignant neoplasm of each participant. The study period was defined as the period from the first PN dose until censoring for each participant. The censoring indications were death, loss to follow-up, change to the other type of CVC, CVC removal without replacement, removal of the last CVC through which PN was administered, and the end of the study. Death and CVC removal were regarded as competing risks. The dates of PN administration and the characteristics of the prescription were collected during the PN period. Data on CVC-related complicationsincluding bloodstream infection, catheter occlusion, drug extravasation, and intravascular thrombosis-were collected for the entire study period. The "PN period" included all the days on which PN was received and up to 14 days after PN was administered. The "non-PN period" included all the days in the study period that did not meet those criteria.
To identify all the episodes of CLABSI, all positive blood cultures obtained during the study period were reviewed and categorized. CLABSI was defined according to the National Healthcare Safety Network (NHSN) criteria, with a modification to include episodes in which a common skin contaminant was isolated from a single blood culture and the treating clinician elected to treat the infection as CLABSI. 20 To identify episodes of occlusion, the institutional pharmaceutical database was queried for all orders for tissue plasminogen activator (TPA) that were entered during the study period; episodes of TPA administration were assumed to indicate CVC occlusion. Urokinase and other thrombolytic agents were not routinely used to treat CVC occlusion at the hospital during the study period.
Statistical Analysis
The demographic characteristics of the matched cohorts were examined with the Wilcoxon signed-rank test for continuous variables or McNemar's test for categorical variables. To minimize the discrepancy among patient characteristics other than the variable of interest, the 2 matched cohorts were used to compare the absolute event rates for the ports and external CVCs. Conversely, the entire cohort was used to assess the differences in risk between the PN period and the non-PN period, as each cohort could act as its own control.
The duration of the PN and non-PN periods and the counts of CVC-related complications during each period were calculated for each patient by summing the days and categorizing each event by period. The rate of each complication was defined as the number of observed events in each period divided by the total duration of that period, with 1 day being added to the observed period for purposes of statistical analysis. To control for correlated observations or matching effect, log-negative binomial models with a generalized estimating equation framework were used to estimate the relative complication rates for the PN and non-PN periods and for children with ports and those with external CVCs during each period. [21] [22] [23] The same technique was used to calculate 95% confidence intervals (95% CIs) for the relative rates, which were considered to be statistically significant if the confidence interval did not include the value 1. Cumulative incidence analyses, stratified by CVC type, were used to compare the incidence of CLABSI according to dichotomous variables, including sex, race (white vs nonwhite), and age (greater than vs less than the median). Because of concerns regarding competing risks and potential violation of the proportional hazards assumption, a modified Fine-Grey analysis was applied. 24, 25 Death and line removal were considered to be competing risks, as each would preclude the occurrence of CLABSI. When there were no events in at least 1 group, Fisher's exact test was used without regard to time at risk; this applied only to the type of malignant neoplasm (hematologic vs solid) for both ports and external CVCs and to patient age for external CVCs. Unadjusted P values <.05 were considered statistically significant for all analyses. Statistical analyses were performed with SAS 9.3 for Windows (SAS Institute, Cary, NC).
Results
Study Population
During the study period, 50 patients who had received PN through ports were identified for inclusion. The characteristics of this population are presented in Table 1 . A matched cohort of 40 patients who received PN through external CVCs was identified by using the algorithm described above (cohort 2). No matches were found for 10 patients. The characteristics of the matched cohorts are also shown in Table 1 . Although children with external CVCs were somewhat younger and received PN for longer periods than did those with ports, matching was otherwise effective in reducing the apparent differences between the 2 groups.
Of the 50 participants with ports, 8 (16%) experienced at least 1 episode of CLABSI during the PN period, and 21 (42%) experienced at least 1 episode of occlusion. The median time from the initiation of PN to the first CLABSI was 58.5 days (range, 22-84 days). Other catheter-related complications that occurred during the PN period included thrombosis (1 episode) and extravasation of PN fluid into the port pocket (4 episodes in 3 participants). One participant developed perforation of the posterior port hub, requiring device removal. The CLABSI rate was markedly higher during the PN period than during the non-PN period (relative risk [RR] = 39.6; 95% CI, 5.0-309; 3.6 vs 0.1 events/1000 days). The rate of occlusion was also significantly higher during the PN period (RR = 10.0; 95% CI, 4.4-22.8; 11.3 vs 0.6 events/1000 days). The event rates for each of these complications during the non-PN period were similar to those in published data for ports in children with cancer (0.11-0.68 for CLABSI 15,26-28 and 2.2 for occlusion 29 ).
Effect of Catheter Type on Risk of Complications During Parenteral Nutrition
Using the entire cohort (n = 90), we compared the relative increase in the rates of complications between the PN and non-PN periods for each CVC type. As with ports, patients with external CVCs showed an increase in the rate of both CLABSI (RR = 2.9; 95% CI, 1.1-7.4; 2.7 vs 0.7 events/1000 days) and occlusion (RR = 2.0; 95% CI, 1.0-4.1; 12.7 vs 3.7 events/1000 days) during the PN period. However, the relative increase in risk of CLABSI during the PN period was significantly greater in children with ports than in those with external CVCs (RR = 39.6 vs 2.9; ratio of relative risks [RRR] = 13.6; 95% CI, 1.4-130.5; P = .02). Likewise, the relative increase in the rate of occlusion during PN was significantly greater in children with ports than in those with CVCs (RR = 10.0 vs 2.0; RRR = 4.9; 95% CI, 1.6-14.5; P = .004).
To determine whether the absolute risk of catheter-related complications during PN administration was affected by catheter type, we compared the rates of these events in the 80 participants constituting the matched cohorts. During the non-PN period, the CLABSI rate was lower in children with ports than in those with external CVCs (RR = 0.2; 95% CI, 0.01-1.2; 0.2 vs 0.7 events/1000 days). However, during the PN period, the rate of CLABSI was paradoxically higher in children with ports, though this difference was not statistically significant (RR = 1.4; 95% CI, 0.5-3.7; 4.6 vs 2.7 events/1000 days). Similarly, during the non-PN period, the rate of occlusion was significantly lower in children with ports (RR = 0.2; 95% CI, 0.06-0.7; 0.6 vs 3.7 events/1000 days), but during the PN period, the rate was not significantly different (RR = 0.7; 95% CI, 0.3-1.5; 8.5 vs 12.7 events/1000 days).
Other Risk Factors for CLABSI During Parenteral Nutrition
During the PN period, children with solid tumors had a higher risk of CLABSI than those with hematologic cancers regardless of CVC type (22% vs 0%; P = .01). For children with external CVCs only, the risk of CLABSI was significantly greater in younger patients than in older patients (29% vs 0%; P = .03). However, age was not a significant predictor of CLABSI risk in children with ports (P = .2). There were no significant differences in the risk of CLABSI by sex (P = .6) or race (P = .7). Patients with solid tumors had a PN period of longer mean duration than did those with hematologic cancers (76 vs 54 days), as did younger children with external CVCs (93 vs 85 days).
Discussion
This study confirms that, despite significant advances in supportive care, children with cancer who receive PN are still at markedly elevated risk of developing CVC-related complications. Four participants had both tunneled and nontunneled external catheters during the study period.
The 2 most frequently identified complications were CLABSI and CVC occlusion. These complications are important, as both are associated with morbidity and mortality in this patient population. 26, [32] [33] [34] These findings emphasize the need to use enteral nutrition wherever possible to avoid this increased risk.
Consistent with the published data, both CLABSI and occlusion appeared to be less frequent in children with ports than in those with external CVCs during the non-PN period. 15, 19, 30, 35 However, during the PN period, there was no significant difference in the absolute complication rates according to CVC type because of a markedly greater increase of risk in children with ports. As shown in Tables 2 and 3 , previous investigations of the effect of device type on CVC complications have yielded conflicting results, but in this study, the usual difference in complication rates between CVC types was eliminated during PN administration. This supports the findings of those studies suggesting that device type does affect the relative risk of complications during PN.
Central Line-Associated Bloodstream Infection
Current evidence suggests that the development of CLABSI in patients with long-term CVCs is related to the development of luminal aggregations of microorganisms in complex communities called biofilm. 36 This biofilm allows microorganisms to remain sessile on the surface of the device, protected from immune and antibiotic killing. The increased risk of CLABSI associated with PN in all CVC types might be related to the sugar and nutrient content of the PN fluid or to increased handling of the CVC during PN administration. Similarly, the greater relative increase in the risk of CLABSI in patients with ports could be related to the increased duration or frequency of transcutaneous needle access, which allows microorganisms access to the luminal surface. 9 This increased risk of CLABSI is important because these infections are associated with additional antibiotic exposure, chemotherapy delay, sepsis, and even mortality. 2 The attributable mortality in pediatric oncology patients is usually estimated at around 2% 26 but has been reported to be as high as 9.6%. 33 In U.S. pediatric oncology patients, CLABSI results in a mean attributable length of hospital stay of 21 days and a mean cost of $69,332. 37 The greater increase in the risk of infection associated with PN use in children with ports is important because it negates the lower infection risk that is a primary advantage of these subcutaneous devices. Furthermore, previous studies have definitively demonstrated that outcomes of CLABSI are significantly worse for patients with ports. Specifically, infections are more likely to be prolonged; the rate of relapse is up to 5-fold higher than that for patients with external CVCs; and the surgical procedures required to remove or replace ports are much more complex. 18, 19 This study used a modified version of the standard NHSN surveillance definition for diagnosing CLABSI. The NHSN definition excludes possible CLABSI events in which only a single blood culture grows a common skin organism, such as one of the coagulase-negative staphylococci, which are the most common etiologic agents of proven CLABSI in pediatric oncology patients. However, the usual practice in many pediatric oncology units is to collect only a single blood culture set from a single-lumen CVC before initiating parenteral antibiotics. 38 As ports are more likely to have only a single lumen, applying the standard definition would lead to an underestimation of the true CLABSI rate and a bias in favor of ports.
Because of the high risk of infection, adjunctive methods of prevention and treatment of CLABSI in pediatric oncology patients with ports should be considered during PN. However, currently available treatments, such as lock therapy with antibiotics or hydrochloric acid, are not well supported by the available data.
2,39-41 A recent study showed that weekly ethanol lock therapy can reduce the risk of CLABSI in pediatric oncology patients, but the investigators did not report whether any participants received PN, and other studies have raised concerns that ethanol lock therapy could damage ports with polyurethane catheters. [42] [43] [44] Patients with solid tumors had a higher incidence of CLABSI than did those with hematologic cancers. This is interesting because, under normal circumstances, the ratio is usually reversed 45, 46 or equal. 15 The reason for this is unclear, but it might be related to the different reasons for PN being required, such as oromotor incoordination in children with brain tumors leading to external contamination of the CVC with oral secretions.
Catheter Occlusion
This study confirms that there is an increased risk of occlusion associated with PN. However, the significantly greater relative risk of occlusion during the PN period, as compared with non-PN period, in children with ports is a novel finding. This is important because occlusion events are associated with clinically significant adverse outcomes. Specifically, up to 20% of occlusion events require CVC replacement, and attempts to clear the obstruction can lead to CVC fracture or rupture. 42, [47] [48] [49] Even after successful treatment of occlusion, the risk of CLABSI and venous thrombosis is significantly elevated. 34, 47, 50 Last, 2 separate studies have shown that pediatric oncology patients who experience CVC occlusion have a higher risk of all-cause mortality. 32, 34 In the context of excellent evidence for associated harm, the marked increase in the risk of occlusion with PN administration, especially in ports, is a major concern. There is evidence that imminent CVC occlusion can be predicted by monitoring catheter resistance, so future studies of this method could focus on children receiving PN.
51,52
Other Complications
Although previous studies have suggested that intravascular thrombosis is more common in children receiving PN, no such difference was detectable in this study, as the absolute number of thrombotic events was low. 53 PN extravasation into the port pocket was seen in 3 patients, with 1 case being related to perforation of the port. Perforation of plastic ports has been described, but PN might have contributed to its occurrence in this case, as it requires frequent, prolonged port access. 54 
Study Strengths and Limitations
This study has several limitations. The retrospective nature of the data collection means that some outcomes or exposures may have been missed or misclassified. Similarly, retrospective matching is imperfect and may fail to account for unrecognized risk factors for outcomes of interest. In this study, the children with ports were slightly older than those with external CVCs, as insertion of subcutaneous devices may be technically difficult in small infants, and this might have affected the risk of CLABSI or occlusion. However, this would not be expected to affect the relative risk ratio between ports and external CVCs, as each cohort acted as its own control for that analysis. The duration of placement and PN administration differed between device types, and the distribution of the risk of complications might change during the period of insertion, affecting the results. External CVCs included both tunneled and nontunneled catheters, which may have different complication rates, thereby introducing some heterogeneity into this group. An alternative explanation of the strong temporal association between PN and CLABSI could be that the requirement for PN is a marker for gastrointestinal tract dysfunction, which in turn might lead to bacteremia by translocation rather than via CVC luminal biofilm. However, data from other studies suggest that most bloodstream infections in pediatric oncology patients are indeed CVC related, and propensity score analysis in adult patients has identified PN as an independent risk factor for CLABSI. 5, 19 The use of TPA administration as a surrogate for CVC occlusion is imperfect and may miss some cases that selfresolved or received alternate management; however, this is unlikely to differ by CVC type. Additionally, the use of TPA has itself been associated with an increased risk for CLABSI, although it is unclear whether this is related to occlusion or to the intervention required to treat it. 50 These findings could be affected by line care regimens, such as the use of CVCs for collecting blood samples for laboratory tests, and by cleaning technique, which can change over time. Such patient-and institution-specific factors may affect generalizability of this study. The use of unadjusted P values to determine the significance of differences between groups could increase the possibility of type 1 error. We did, however, predetermine that differences in the complication rates for CVC types during PN administration would be the primary analysis, so the interpretation of this outcome is not affected.
Although the retrospective nature of the study is a limitation, the relative homogeneity of this pediatric oncology patient population treated contemporaneously at a single center reduced the risk that unrecognized variations in institutional practice would affect the results. Furthermore, using a carefully matched cohort to compare absolute complication rates ameliorated the effect of some potential confounders on the results, such as the type of cancer, hematopoietic stem cell transplantation status, and patient age. 55 A generalized estimating equation framework was used for the analysis, allowing us to control for potentially correlated observations, such as an increased risk of subsequent CLABSI after a first episode, and to preserve statistical power. Similarly, using each cohort as its own control for the comparison of the relative risk of complications between PN and non-PN periods for each CVC type reduced the risk of unrecognized differences between cohorts affecting the analysis. Finally, using the modified NHSN criteria for retrospective diagnosis of CLABSI allowed a pragmatic categorization of positive blood cultures that was not biased by the more frequent collection of paired blood cultures from external catheters than from ports.
Implications for Clinical Practice and Future Research
Guidelines from the European Society for Clinical Nutrition and Metabolism for PN in adults and from the European Society for Clinical Nutrition and Metabolism and the European Society for Paediatric Gastroenterology Hepatology and Nutrition for PN in children both recommend the preferential use of external CVCs in patients who will require mediumto long-term PN. 56, 57 However, the evidence provided to support these recommendations was limited. The pediatric guidelines state that the recommendation for avoidance of ports is level of evidence 2+, which is defined as being based on "well conducted case-control or cohort studies with a low risk of confounding, bias, or chance and a moderate probability that the relationship is causal." The adult guidelines state that ports are appropriate for medium-term use but that "for prolonged use and home parenteral nutrition (>3 months) . . . requiring frequent (daily) access, a tunneled device is generally preferable." The present study supports the recommendations in these guidelines. However, even relatively short-term administration of PN was associated with a significant complication risk in children with ports, with the median time to first CLABSI being <2 months. Some options available for pediatric oncology patients with ports who subsequently require PN include removing the port and replacing it with an external CVC; inserting a temporary external CVC; adding adjunctive prophylaxis, such as ethanol or antibiotic catheter lock therapy; and close monitoring for complications without adjunctive therapy. There is currently insufficient evidence to support favoring any of these options, and more research examining these interventions during the PN period is needed.
Conclusions
There is a marked increase in the risk of CLABSI and CVC occlusion in pediatric oncology patients receiving PN. These complications are important, as they can have a major effect on the provision of chemotherapy and other life-sustaining care. Enteral feeding should be used wherever possible to reduce the requirement for PN, but this is often unachievable. In this study, the relative increase in the risk of CLABSI and occlusion during PN administration was much greater in patients with ports than in those with external CVCs, eliminating the usual protective effect of ports. Consequently, during the PN period, the rates of infection and occlusion were similar for both CVC types. Furthermore, because ports carry a much higher risk of CLABSI relapse and are more challenging to replace than external CVCs, the clinical significance of occlusion and infection is greater in children with ports. Therefore, although the optimal management of pediatric oncology patients with ports who subsequently require initiation of PN remains unclear, adjunctive therapy to prevent these complications may be indicated. If a pediatric oncology patient is known to require PN at the time that CVC insertion is planned, strong consideration should be given to the primary insertion of an external catheter to avoid the risks associated with port-related complications. Figure S1 is available with the article online at http://journals .sagepub.com/home/pen Wolf drafted the manuscript; and all authors critically revised the manuscript, read and approved the final manuscript, and agree to be fully accountable for ensuring the integrity and accuracy of the work.
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